Stockreport

MediNova's MN-166 reduced progression of MS by 26% in mid-stage study [Seeking Alpha]

MediciNova, Inc.  (MNOV) 
Last medicinova, inc. earnings: 4/23 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: medicinova.com/investor-relations/media-archive
PDF MediNova's MN-166 reduced progression of MS by 26% in mid-stage studyMediciNova's (NASDAQ:MNOV) lead candidate MN-166 (ibudilast) demonstrated atreatment effect in a Pha [Read more]